BCEL Atreca Inc

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences:

Canaccord Genuity Horizons in Oncology Virtual Event Wednesday, April 8, 2020 Panel time: 12:45 p.m. EDT

19th Annual Needham Virtual Healthcare Conference Wednesday, April 15, 2020 Presentation time: 2:50 p.m. EDT

Live webcasts of each event can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays of the webcasts will be available on the Company's website for 90 days following the live presentations.

About Atreca, Inc.Atreca is a biopharmaceutical company developing novel antibody-based cancer immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

ContactsAtreca, Inc. Herb Cross Chief Financial Officer info@atreca.com

Investors: Alex Gray, 650-779-9251agray@atreca.com

Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com

Source: Atreca, Inc.